Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
Year: 2016
Type: review
Source: Leukemia
DOI: 10.1038/leu.2016.12
Institutions: RWTH Aachen University, Tufts University, Tufts Medical Center, Roskilde Sygehus, Copenhagen University Hospital, Policlinico San Matteo Fondazione, Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Inserm, Hôpital Saint-Louis, Université Paris Diderot, Centre d'Investigation Clinique Saint-Louis, University of Freiburg, University Medical Center Freiburg, Heidelberg University, Medizinische Fakultät Mannheim, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Weill Cornell Medicine, Ospedale Papa Giovanni XXIII
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: Philadelphia-negative myeloproliferative neoplasms, inflammation, JAK/STAT signaling, JAK2 V617F mutation, CALR mutation, somatic mutations, anti-inflammatory therapy, immune-modulating drugs, MPN pathogenesis, differential diagnosis, malignant clone, hematopoietic stem and progenitor cells
Open Access status: green
Funder: European Hematology Association
Award: G5840516970
OpenAlex ID: W2254008564
